CancerDrs Find care

Bladder Cancer clinical trials in Kansas

21 actively recruiting bladder cancer trials at 27 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Kansas:
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…

Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in Kansas:
  • Wichita Urology Group — Wichita, Kansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …

Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in Kansas:
  • Wichita Urology Group — Wichita, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Kansas:
  • Cancer Center of Kansas - Chanute — Chanute, Kansas
  • Cancer Center of Kansas - Dodge City — Dodge City, Kansas
  • Cancer Center of Kansas - El Dorado — El Dorado, Kansas
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • Central Care Cancer Center - Garden City — Garden City, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
  • University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…

Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Kansas:
  • The University of Kansas Cancer Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic downstaging and quality of life in MIBC cisp…

Sponsor: University of Kansas Medical Center
NCT ID: NCT06493370
Sites in Kansas:
  • The University of Kansas Cancer Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Kansas:
  • The University of Kansas Cancer Center, Investigational Drug Services — Fairway, Kansas
  • The University of Kansas Clinical Research Center — Fairway, Kansas
  • The University of Kansas Hospital — Kansas City, Kansas
  • The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
  • University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults wh…

Sponsor: Pfizer
NCT ID: NCT07206225
Sites in Kansas:
  • The University of Kansas - Clinical Research Center — Fairway, Kansas
  • The University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
  • The University of Kansas Hospital — Kansas City, Kansas
  • The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
  • The University of Kansas Hospital - Indian Creek Campus — Overland Park, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
  • Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Kansas:
  • Saint Luke's Cancer Instititute - South — Overland Park, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Measuring Surgical Recovery After Radical Cystectomy

The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed …

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03193970
Sites in Kansas:
  • University of Kansas Medical Center — Lawrence, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)

This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care. The study team found in a previous study that resting energy can be dif…

Sponsor: University of Kansas Medical Center
NCT ID: NCT06721260
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

The purpose of this study is to create a registry, which is a "bank" of information about patients who have had similar medical conditions and treatments. The registry will be used by researchers to learn more about long term outcome of pa…

Sponsor: University of Kansas Medical Center
NCT ID: NCT03413982
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

LaserEn: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors

Conventional monopolar or bipolar transurethral resection of bladder tumors is the most common method for resection of a bladder mass. En bloc resection has demonstrated success in the literature utilizing different techniques and lasers, …

Sponsor: University of Kansas Medical Center
NCT ID: NCT04979156
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20